Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Imricor Medical Systems's Enterprise Value is A$677.98 Mil.
Imricor Medical Systems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-29.00 Mil. Therefore, Imricor Medical Systems's EV-to-OCF for today is -23.38.
The historical rank and industry rank for Imricor Medical Systems's EV-to-OCF or its related term are showing as below:
ASX:IMR'
s EV-to-OCF Range Over the Past 10 Years
Min: -23.01 Med: -6.53 Max: 0.34
Current: -23.01
During the past 8 years, the highest EV-to-OCF of Imricor Medical Systems was 0.34. The lowest was -23.01. And the median was -6.53.
ASX:IMR's EV-to-OCF is ranked better than 88.5% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.81
vs ASX:IMR: -23.01
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imricor Medical Systems (ASX:IMR) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imricor Medical Systems's PE Ratio (TTM) for today is calculated as:
Imricor Medical Systems's share price for today is A$1.93.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imricor Medical Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.122.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's EV-to-OCF falls into.
Imricor Medical Systems's current Enterprise Value is A$677.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imricor Medical Systems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-29.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a EV-to-OCF of -23.38 as of Jul. 29, 2026. According to the industry distribution chart, Imricor Medical Systems ranks #98 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 11.5%.
Is Imricor Medical Systems' EV-to-OCF too high?
Imricor Medical Systems' current EV-to-OCF is -23.38. Based on the distribution chart, Imricor Medical Systems ranks #98 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #98 out of 852 companies for EV-to-OCF. This places Imricor Medical Systems in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.81, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current EV-to-OCF is -23.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.93 — trading 1830% above its estimated fair value. The current EV-to-OCF is -23.38. Imricor Medical Systems' overall GF Score™ is 42/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current EV-to-OCF is -23.38 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.93 is trading 1830% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
EV-to-OCF: -23.38
GF Value™: A$0.10 vs. price of A$1.93 (1830% above fair value)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
42GF Score
Get the complete analysis for ASX:IMR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
